Valuation: Eupraxia Pharmaceuticals Inc.

Market Cap 627M 450M 403M 370M 336M 42.7B 639M 4.42B 1.77B 22.46B 1.69B 1.65B 70.83B P/E 2026 *
-6.73x
P/E 2027 * -6.62x
Enterprise Value 627M 450M 403M 370M 336M 42.7B 639M 4.42B 1.77B 22.46B 1.69B 1.65B 70.83B EV / Sales 2026 *
-
EV / Sales 2027 * 884x
Free-Float
87.89%
Yield 2026 *
-
Yield 2027 * -
1 day-6.11%
1 week-0.52%
1 month-26.71%
3 months+6.01%
6 months-10.61%
Current year-7.75%
1 week 8.94
Extreme 8.94
10.46
1 month 8.94
Extreme 8.94
11.43
Current year 7.85
Extreme 7.85
13.08
1 year 7.35
Extreme 7.35
13.08
3 years 3.07
Extreme 3.07
13.08
5 years 0.8
Extreme 0.8
13.08
10 years 0.8
Extreme 0.8
13.08
Manager TitleAgeSince
Chief Executive Officer - 2012-07-22
Director of Finance/CFO - 2025-02-17
Chief Tech/Sci/R&D Officer 50 2026-07-12
Director TitleAgeSince
Chairman 58 2013-01-13
Director/Board Member - 2012-07-22
Director/Board Member 61 2013-01-13
Date Insider Type Main position Quantity % Market Cap. Importance
9/23/26 Sell

Director

-387,300 0.5876%
9/23/26 Sell

Director

-1,200,000 1.8208%
9/23/26 Sell

Director

-1,215,280 1.8439%
Change 5-day change 1-year change 3-year change Capi.($)
-6.11%-0.52%+19.00%+88.51% 450M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.31%+6.73%+44.72%+184.34% 39.48B
Weighted average by Cap. +0.17%+5.44%+47.96%+176.57%

Financials

2026 *2027 *
Net sales - 710K 509K 456K 419K 380K 48.3M 723K 5M 2.01M 25.41M 1.91M 1.87M 80.13M
Net income -92.49M -66.29M -59.37M -54.61M -49.48M -6.29B -94.22M -651M -261M -3.31B -249M -243M -10.44B -104M -74.44M -66.67M -61.32M -55.56M -7.07B -106M -731M -294M -3.72B -279M -273M -11.73B
Net Debt - -
Projected Income Statement - Annual - Eupraxia Pharmaceuticals Inc.
Logo Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Employees
-
Date Price Change Volume
26-10-30 $9.520 -6.11% 115,159
26-10-29 $10.14 -1.36% 83,499
26-10-28 $10.28 +3.01% 87,990
26-10-27 $9.980 +4.50% 111,051
26-10-26 $9.550 -0.21% 52,748
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Eupraxia Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
9.520CAD
Average target price
16.33CAD
Spread / Average Target
+71.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eupraxia Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. EPRX Stock